




TRANSGENOMIC®
the power of discovery



**Publications Citing
SURVEYOR® Nuclease
for Mutation Detection
and Analysis**

www.transgenomic.com

Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.

Nickerson ML, Jaeger E, Shi Y, Durocher JA, Mahurkar S, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Mukeria A, Holcatova I, Schmidt LS, Toro JR, Karami S, Hung R, Gerard GF, Linehan WM, Merino M, Zbar B, Boffetta P, Brennan P, Rothman N, Chow WH, Waldman FM, Moore LE.
Clin Cancer Res. 14, 4726-34 (2008).

Novel method for genomic analysis of PKD1 and PKD2 mutations in autosomal dominant polycystic kidney disease.

Tan YC, Blumenfeld JD, Anghel R, Donahue S, Belenkaya R, Balina M, Parker T, Levine D, Leonard DG, Rennert H.
Hum. Mutat. Oct 3. [Epub ahead of print] (2008).

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.

Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X, Naoki K, Okamoto I, Nakagawa K, Yeap BY, Meyerson M, Wong KK, Richards WG, Sugarbaker DJ, Johnson BE, Jänne PA.
Br. J. Cancer. 99, 245-52 (2008).

Development of a simple and highly sensitive mutation screening system by enzyme mismatch cleavage with optimized conditions for standard laboratories.

Tsuji T, Niida Y.
Electrophoresis 29, 1473-83 (2008).

Comparison of the mismatch-specific endonuclease method and denaturing high-performance liquid chromatography for the identification of HBB gene mutations.

Hung CC, Su YN, Lin CY, Chang YF, Chang CH, Cheng WF, Chen CA, Lee CN, Lin WL.
BMC Biotechnol. 8, 62-70 (2008).

TILLMore, a resource for the discovery of chemically induced mutants in barley

Talamè V, Bovina R, Sanguineti MC, Tuberosa R, Lundqvist U, Salvi S.
Plant Biotechnol. J. 6, 477-485 (2008).

NPBS2 screening with SURVEYOR in Hellenic children with steroid-resistant nephrotic syndrome.

Voskarides K, Makariou C, Papagregoriou G, Stergiou N, Printza N, Alexopoulos E, Elia A, Papachristou F, Pierides A, Georgaki E, Deltas C.
Pediatr. Nephrol. 23, 1373-1375 (2008).

Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.

Thomas, H, Ezzeldin H, Guarcello V, Mattison L, Fridley B and Diasio R.
Pharmacogenet. Genomics 18; 25-35. (2008).

Rapid identification of mitochondrial DNA (mtDNA) mutations in neuromuscular disorders by using surveyor strategy.

Bannwarth S, Procaccio V, Rouzier C, Fragaki K, Poole J, Chabrol B, Desnuelle C, Pouget J, Azulay J, Attarian S, Pellissier J, Gargus J, Abdenur J, Mozaffar T, Calvas P, Labauge P, Pages M, Wallace D, Lambert J and Paquis-Flucklinger V.
Mitochondrion 8, 136-145 (2008).

Screening human genes for small alterations performing an enzymatic cleavage mismatched analysis (ECMA) protocol.

Vogiatzakis N, Kekou K, Sophocleous C, Kitsiou S, Mavrou A, Bakoula C, Kanavakis E.
Mol. Biotechnol. 37 12-9 (2007).

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM.
N. Engl. J. Med. Dec 20;357(25):2552-61. (2007).

Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.

Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB.
Pharmacogenet Genomics. Nov;17(11):973-87. (2007).

Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy.

Mitani N, Niwa Y, Okamoto Y.
Ann. Clin. Biochem. Nov;44(Pt 6):557-9. (2007)

s-RT-MELT for rapid mutation scanning using enzymatic selection and real time DNA-melting: new potential for multiplex genetic analysis.

Li J, Berbeco R, Distel RJ, Jänne PA, Wang L, Makrigiorgos GM.
Nucleic Acids Res. 35(12):e84. Epub 2007 Jun 1. (2007).

Development of a rapid, reliable genetic test for Pseudoxanthoma Elasticum.

Shi Y, Terry SF, Terry PF, Bercovitch LG, Gerard GF.
J. Mol. Diagn. 9, 105-112. (2007).

KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to Imatinib mesylate.

Mitsuhashi T, Nakayama M, Sakurai S, Fujimura M, Shimizu Y, Ban S, Ogawa F, Hirose T, Ishihara O, Shimizu M.
Ann. Diagn. Pathol. 11, 49-54. (2007).

Rapid identification of unknown heteroplasmic mutations across the entire human mitochondrial genome with mismatch-specific Surveyor nuclease.

Bannwarth S, Procaccio V, Paquis-Flucklinger V.
Nat. Protoc. 1, 2037-2047. (2006).

Surveyor nuclease-based genotyping of SNPs.

Mitani N, Tanaka S, Okamoto Y.
Clin. Lab. 52, 385-6. (2006).

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR -amplified lung cancer.

Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Janne PA.
J. Clin. Invest. 116, 2695-2706. (2006).

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study.

Giaccone G, Gallegos Ruiz M, Le Chevalier T, Thatcher N, Smit E, Rodriguez JA, Janne P, Oulid-Aissa D, Soria JC.
Clin. Cancer Res. 12, 6049-6055. (2006).

Genetic predictors of adverse radiotherapy effects: the Gene-PARE project.

Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B, Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, Trop CS, Park J, Rosenstein BS.
Int. J. Radiat. Oncol. Biol. Phys. 65, 646-655. (2006).

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.

Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borrás AM, Bailey C, de Jong F, Janne PA, Johnson BE.
J. Clin. Oncol. 24, 4517-4520. (2006).

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with Gefitinib or Erlotinib.

Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Janne PA.
Clin. Cancer Res. 12, 3908-3914. (2006).

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation.

Jamieson CH, Gotlib J, Durocher JA, Chao MP, Mariappan MR, Lay M, Jones C, Zehnder JL, Lilleberg SL, Weissman IL.
Proc. Natl. Acad. Sci. 103, 6224-6229. (2006).

A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.

Janne PA, Borrás AM, Kuang Y, Rogers AM, Joshi VA, Liyanage H, Lindeman N, Lee JC, Halmos B, Maher EA, Distel RJ, Meyerson M, Johnson BE.
Clin. Cancer Res. 12, 751-758. (2006).

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Janne PA, Johnson BE.
Clin. Cancer Res. 12, 4416s-4420s. (2006).

Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region.

Nakayama M, Mitsuhashi T, Shimizu Y, Ban S, Ogawa F, Ishihara O, Shimizu M.
Int. J. Gynecol. Pathol. 25, 70-76. (2006).

Mutation analysis of hCDC4 in AML cells identifies a new intronic polymorphism.

Nowak D, Mossner M, Baldus CD, Hopfer O, Hofmann WK.
Int. J. Med. Sci. 3, 148-151. (2006).

Temperature-mediated heteroduplex analysis for the detection of drug-resistant gene mutations in clinical isolates of Mycobacterium tuberculosis by denaturing HPLC, SURVEYOR nuclease.

Shi R, Otomo K, Yamada H, Tatsumi T, Sugawara I.
Microbes Infect. 8, 128-135. (2006).

A new detection method for ATRX gene mutations using a mismatch-specific endonuclease.

Wada T, Fukushima Y, Saitoh S.
Am. J. Med. Genet. A 140, 1519-1523. (2006).

A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples.

Sattler M, Walz C, Crowley BJ, Lengfelder E, Janne PA, Rogers AM, Kuang Y, Distel RJ, Reiter A, Griffin JD.
Blood 107, 1237-1238. (2006).

Surveyor™ Nuclease: A new strategy for a rapid identification of heteroplasmic mitochondrial DNA mutations in patients with respiratory chain defects.

Bannwarth S, Procaccio V, Paquis-Flucklinger V.
Hum. Mutat. 25, 575-582. (2005).

Localization, mobility and fidelity of retrotransposed Group II introns in rRNA genes.

Conlan LH, Stanger MJ, Ichiyanagi K, Belfort M.
Nucleic Acids Res. 33, 5262-5270. (2005).

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, Kajiguchi T, Ruan J, Lilleberg SL, Durocher JA, Lichy JH, Wang Y, Cohen PS, Arber DA, Heinrich MC, Neckers L, Galli SJ, Gilliland DG, Coutre SE.
Blood 106, 2865-2870. (2005).

A method for clone sequence confirmation using a mismatch-specific DNA endonuclease.

Qiu P, Shandilya H, Gerard GF.
Mol. Biotechnol. 29, 11-18. (2005).

A structured mutant population for forward and reverse genetics in Barley (*Hordeum vulgare* L.).

Caldwell DG, McCallum N, Shaw P, Muehlbauer GJ, Marshall DF, Waugh R.
Plant J. 40, 143-150. (2004).

Improving specificity of DNA hybridization-based methods.

Chalaya T, Gogvadze E, Buzdin A, Kovalskaya E, Sverdlov ED.
Nucleic Acids Res. 32, e130. (2004).

Mutation detection using Surveyor™ nuclease.

Qiu P, Shandilya H, D'Alessio JM, O'Connor K, Durocher J, Gerard GF.
Biotechniques 36, 702-707. (2004).

Heteroduplex detection with a plant DNA endonuclease for standard gel electrophoresis.

Scaffino MF, Pilotto A, Papadimitriou S, Sbalzarini M, Ansaldi S, Diegoli M, Porcu E, Grasso M, Brega A, Arbustini E.
Transgenics 4, 157-166. (2004).

Corporate Headquarters
Transgenomic, Inc.
12325 Emmet Street
Omaha, NE 68164 United States
Toll-free: (888) 233-9283
Phone: (402) 452-5400
Fax: (402) 452-5401
E-mail: info@transgenomic.com

Europe
Transgenomic Ltd.
40 Watt Road, Hillington Park Glasgow
G52 4RY, UK
Phone: +44 (0) 141 892 8800
Fax: +44 (0) 141 883 5967
E-mail: sales@transgenomic.com

